Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial

Rossano, J; Canter, C; Wolf, C; Favatella, N; Lockman, J; Puli, S; Javidialsaadi, A; Dyme, J; Crevar, C; Mital, S

doi:10.1016/j.ahj.2025.107283

Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial

Am Heart JPublished 30 Sep 2025phase 3, randomized, placebo-controlled, double-blind, parallel-group, multicenter, international study

Read the original article ↗PubMed

Cite

Study context

Population: Symptomatic adolescent patients (12 years to <18 years old) with obstructive hypertrophic cardiomyopathy (HCM)

Planned comparison: Mavacamten or placebo for 28 weeks
Primary endpoint: Change from baseline in Valsalva LVOT gradient
Follow-up: Week 28

Methodological details1:1 randomization, 28-week active-treatment period with placebo crossover to mavacamten, open-label long-term extension period for ≤144 weeks

1:1 randomization
28-week active-treatment period with placebo crossover to mavacamten
Open-label long-term extension period for ≤144 weeks

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial. Am Heart J. Published 30 September 2025. doi:10.1016/j.ahj.2025.107283

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →